Meeting
2020 Genitourinary Cancers Symposium
ModraDoc006, an oral docetaxel formulation in combination with ritonavir (ModraDoc006/r), in metastasized castration-resistant prostate cancer (mCRPC): A multicenter phase I study.
Authors
Marit Vermunt
Department of Clinical Pharmacology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, Netherlands
Marit Vermunt , Debbie Robbrecht , Lot Devriese , Julie Janssen , Marianne Keessen , Ferry Eskens , Jos H. Beijnen , Niven Mehra , Andre M. Bergman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03136640
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 79)
Abstract #
79
Poster Bd #
D3
Abstract Disclosures
Similar Posters
Poster
2020 Genitourinary Cancers Symposium
Dose-escalation results of a phase I study of 225Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC).
First Author: Scott T. Tagawa
Poster
2017 ASCO Annual Meeting
Phase I dose-escalation study of fractionated-dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC).
First Author: Scott T. Tagawa
Poster
2017 Genitourinary Cancers Symposium
A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 in patients with mCRPC.
First Author: Michael Paul Kolinsky
Poster
2016 ASCO Annual Meeting
Combination therapy with enzalutamide and the poly (ADP-ribose) polymerase-1 (PARP1) inhibitor niraparib in castration-resistant prostate cancer (CRPC): HCRN GU 14-202.
First Author: John Paul Flores